Ankylosing spondylitis

Looking Ahead: Prognosis for Ankylosing Spondylitis

The prognosis for ankylosing spondylitis (AS) varies from one person to another and largely depends on the severity of the disease, the extent of the symptoms, and how early and effectively the disease is managed. With patience, perseverance, and a proactive approach to health care, it is possible to live a full life with AS.

In this article, we’ll explore the factors that influence the outlook of life with AS, and discuss the long-term considerations you should be aware of. 

Disease Progression Is Variable

The rate of disease progression in ankylosing spondylitis varies greatly from person to person. Some individuals may experience a slow progression of symptoms over many years, while others may face a more rapid progression. It’s important to keep in mind that the disease does not follow a predictable course.

Several factors can influence the rate of progression in AS. Genetic factors, such as the presence of the HLA-B27 gene, can play a role. Individuals with this gene may be more likely to experience a more severe disease course, although this is not always the case. (Source)

Physical symptoms and their progression can also vary. Some with AS experience only mild back pain and stiffness, while others may have severe pain and significant loss of spinal mobility. In some cases, AS can lead to complications such as spinal fusion, where the vertebrae become fused together, leading to a rigid spine. (Source)

Early Diagnosis Is Critical

Early diagnosis of ankylosing spondylitis is a critical factor that can significantly influence the course of the disease. It opens the door to early and effective treatment strategies, leading to better management of symptoms, prevention of complications, and overall improved long-term outcomes. (Source, Source)

  • early intervention and treatment: One of the primary benefits of early diagnosis is the opportunity for early intervention. Starting treatment soon after the onset of symptoms can help control inflammation, relieve pain, and reduce stiffness. This early management is essential in preventing or slowing the progression of the disease, particularly in preventing the fusion of the spine and other joints, a major concern in AS.
  • prevention of structural damage: AS can lead to irreversible structural damage to the spine and other joints over time. Early diagnosis allows for timely treatment that can potentially prevent or minimize this damage. Biologic medications, such as TNF inhibitors, are particularly effective in this regard and are more likely to be successful when started early.
  • improved functional outcomes: Early treatment can lead to better functional outcomes. It can preserve mobility and flexibility, allowing you to maintain your daily activities and quality of life. This is particularly important in AS, where spinal rigidity and joint damage can significantly impair physical function.
  • reduced risk of complications: Early diagnosis and management of AS can help in monitoring for complications such as uveitis and cardiovascular disease, as well as in implementing preventive strategies.
  • enhanced quality of life: Early control of symptoms can significantly improve your quality of life. It can reduce pain and stiffness, improve sleep, and decrease fatigue, which are common issues in AS. This improvement in symptoms can also positively affect mental health, reducing the risk of depression and anxiety, which are higher in chronic disease conditions.
  • better long-term prognosis: Overall, early diagnosis and subsequent management of AS can lead to a better long-term prognosis. It can slow disease progression, reduce the risk of severe disability, and allow you to lead a more active and fulfilling life.

Treatment Impact

The impact of treatment on the prognosis of ankylosing spondylitis is significant. Early diagnosis and treatment can help manage symptoms, slow the progression of the disease, and maintain a good quality of life. (Source)

Treatment for AS typically involves a combination of medication, physical therapy, and lifestyle changes. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) inhibitors, and Janus kinase (JAK) inhibitors are used to reduce inflammation, relieve pain, and potentially slow the progression of the disease. (Source)

With effective treatment, your outlook for leading an active and productive life is positive. The main goals of treatment are to relieve pain and stiffness, maintain good posture, prevent or delay spinal deformity, and maintain the ability to work and function in daily activities.

Medications are primarily used to manage AS symptoms, reduce inflammation, and slow down Medication Effectiveness

the progression of the disease. Nonsteroidal anti-inflammatory drugs (NSAIDs), for instance, are often the first line of treatment and can significantly alleviate pain and stiffness. (Source)

The advent of biologic medications has marked a significant turning point in the management of ankylosing spondylitis. These advanced therapies have not only transformed the treatment landscape but have also considerably enhanced the long-term outlook for many individuals living with this condition.

Tumor necrosis factor (TNF) inhibitors and Janus kinase (JAK) inhibitors, for example, work by targeting specific components of the immune system to reduce inflammation. Their effectiveness can lead to improved mobility, reduced pain, and a better overall quality of life. (Source, Source)

However, the effectiveness of these medications can vary greatly from one person to another due to factors such as genetic variations, disease severity, and the presence of other health conditions. A given medication may bring significant symptom relief to some, while others may not see the same benefits or may experience unacceptable side effects.

The timing of medication initiation can also influence the prognosis. Early intervention with appropriate medication can potentially slow the progression of AS and prevent irreversible damage to the spine and other joints. Therefore, the effectiveness of medication, along with early diagnosis and treatment, can significantly affect the long-term prognosis of individuals with AS.


Complications of ankylosing spondylitis can significantly affect the prognosis of the disease. These complications can range from physical manifestations such as spinal fusion and joint damage, to systemic issues such as cardiovascular disease and eye inflammation (uveitis).

  • Spinal fusion, a common complication of AS, can lead to a rigid, inflexible spine, significantly affecting mobility and quality of life. This can also affect the ability to perform daily activities and may lead to disability. Joint damage, particularly in the hips, can also result in reduced mobility and increased pain. (Source)
  • Systemic complications such as cardiovascular disease are also a concern in AS. Inflammation can spread to the aorta, the main artery from the heart, leading to aortitis, which can increase the risk of heart failure. This can significantly affect the prognosis and may require additional medical management. (Source)
  • Eye inflammation, or uveitis, is another common complication of AS. If not promptly treated, it can lead to vision loss, which can significantly affect quality of life and independence. (Source)
  • Lung disease and kidney problems can further complicate the prognosis and management of the disease. Lung disease can lead to breathing difficulties, while kidney problems can affect the body's ability to filter waste and toxins. (Source)
  • Mental health issues such as depression and anxiety are also common in people with AS due to the chronic nature of the disease and its impact on quality of life. These conditions can further complicate the disease prognosis, as they can affect the ability to cope with the disease, adhere to treatment plans, and maintain overall well-being. (Source)

Lifestyle Factors

Lifestyle modifications can have a profound effect on the prognosis of ankylosing spondylitis. While medication and physical therapy are essential components of managing the condition, lifestyle changes can help manage symptoms, slow disease progression, and improve overall quality of life. Of course, your situation is unique, and it's important to consult with your health care provider or care team to ensure any lifestyle changes you make are safe and appropriate for you.

  • Regular physical activity is crucial. Exercise can help maintain flexibility, improve posture, and strengthen the muscles supporting the spine. It can also help manage pain and fatigue associated with AS. A balanced exercise regimen that includes stretching, strength training, and low-impact aerobic activities such as swimming or cycling is often recommended. (Source)
  • Diet plays a role in managing AS. While there's no specific AS diet, a balanced, nutritious diet can support overall health and potentially reduce inflammation. It’s possible you will find that certain foods exacerbate your symptoms, so maintaining a food diary and discussing it with a health care provider can be beneficial. (Source)
  • Sleep is another important aspect. AS can cause discomfort and pain that disrupts sleep, but good sleep hygiene can help. This includes maintaining a regular sleep schedule, creating a comfortable and supportive sleeping environment, and avoiding stimulants like caffeine close to bedtime. (Source)
  • Stress management is also essential. Living with a chronic illness like AS can be stressful, which in turn can exacerbate symptoms. Techniques such as mindfulness, meditation, and deep breathing can help manage stress levels. Additionally, joining a support group or seeking psychological counseling can provide emotional support and coping strategies. (Source)
  • Smoking cessation is strongly advised for individuals with AS. Smoking can worsen symptoms and accelerate disease progression by increasing inflammation and damaging the lungs. (Source)

Individual Variability

Individual variability plays a significant role in predicting the prognosis of ankylosing spondylitis, making it a condition with highly personalized outcomes. This variability stems from a combination of genetic, environmental, and lifestyle factors, which can influence the severity of symptoms, the rate of disease progression, and the response to treatment. This variability underscores the importance of personalized treatment approaches and regular monitoring to adapt management strategies to each individual's unique circumstances and needs.

  • genetic factors: Genetic predispositions, including the presence of the HLA-B27 gene, can affect disease severity and progression. However, not everyone with this gene develops severe forms of AS, indicating that other genetic factors also play a role. (Source)
  • environmental influences: Environmental factors, such as exposure to toxins, can affect the onset and progression of AS. The interaction between these factors and an individual’s genetic makeup can vary greatly, influencing the disease course. (Source)
  • lifestyle and health behaviors: Lifestyle choices, including physical activity levels, smoking, and diet, significantly affect AS prognosis. For instance, regular exercise can improve symptoms and slow progression, while smoking has been linked to worse outcomes.
  • comorbid conditions: The presence of comorbid conditions, such as cardiovascular disease or diabetes, can also influence the prognosis of AS. These conditions can complicate management and may accelerate disease progression.
  • response to treatment: There is considerable variability in how individuals respond to treatments, including NSAIDs and biologics such as TNF inhibitors. This variability can affect symptom control and long-term outcomes.
  • disease activity and severity: The initial severity and activity level of the disease can vary, influencing the prognosis. Early and aggressive forms of AS tend to have a different prognosis compared to milder or later-onset forms.

How WellTheory Can Help

At WellTheory, we understand the intricacies of navigating autoimmunity — many members of our care team have personal experiences with autoimmune conditions. Our approach is personalized and holistic, encompassing all aspects of your well-being. Here’s how we can support you:

  • personalized care for your unique journey: Autoimmunity affects everyone differently. We take into account your symptoms, lifestyle, and goals to create a care plan that’s uniquely yours.
  • daily guidance and collaborative effort: Living with an autoimmune condition requires continuous care and support. Our collaborative approach ensures that you’re an active participant in your care.
  • evidence-based, data-driven care plans: Our strategies are grounded in the latest scientific evidence to ensure you receive the best advice and guidance.

The Bottom Line

A diagnosis of ankylosing spondylitis, though challenging, is filled with hope and potential for a fulfilling life. The advancements in medical treatments, particularly with biologic medications, have opened doors to effective management of the condition, significantly improving the quality of life for many. Early diagnosis plays a pivotal role in this journey, as timely intervention can help manage symptoms and prevent long-term complications.

Remember, your journey with AS is unique, and there’s strength in the support and understanding of a community that shares your experiences. With ongoing research and developments in medical science, the future holds even more promise for better management and understanding of AS. Stay hopeful and empowered, knowing that with the right care, lifestyle adjustments, and support, you can navigate this journey successfully and lead a life that's rewarding and full of possibilities.

References (2020, April 17). Stages and progression. Health Union. (2023, April 28). JAK inhibitors. Health Union.

Baraliakos, X., Haibel, H., Fritz, C., Listing, J., Heldmann, F., Braun, J., & Sieper, J. (2013). Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Research & Therapy, 15(3), R67.

Bhattad, P. B., Kulkarni, M., Patel, P. D., & Roumia, M. (2022). Cardiovascular morbidity in ankylosing spondylitis: A focus on inflammatory cardiac disease. Cureus, 14(6), e25633.

Cleveland Clinic. (2022, September 15). Best types of exercises for ankylosing spondylitis.

Fan, M., Liu, J., Zhao, B., Wu, X., Li, X., & Gu, J. (2020). Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials. Experimental and Therapeutic Medicine, 19(4), 3031–3041.

Hanson, A., & Brown, M. A. (2017). Genetics and the causes of ankylosing spondylitis. Rheumatic Diseases Clinics of North America, 43(3), 401–414.

Kaut, I. K., Abourazzak, F. E., Jamila, E., Sènami, F. A., Diketa, D., & Taoufik, H. (2017). Axial spondyloarthritis and cigarette smoking. Open Rheumatology Journal, 11, 53–61.

Macfarlane, T. V., Abbood, H. M., Pathan, E., Gordon, K., Hinz, J., & Macfarlane, G. J. (2018). Relationship between diet and ankylosing spondylitis: A systematic review. European Journal of Rheumatology, 5(1), 45–52.

Malaviya, A. P., & Ostor, A. J. (2011). Early diagnosis crucial in ankylosing spondylitis. The Practitioner, 255(1746), 21–22.

Mauro, D., Forte, G., Poddubnyy, D., & Ciccia, F. (2024). The role of early treatment in the management of axial spondyloarthritis: Challenges and opportunities. Rheumatology and Therapy, 11, 19–34.

Mercieca, C., van der Horst-Bruinsma, I. E., & Borg, A. A. (2014). Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; Implications for clinical practice. Current Rheumatology Reports, 16(8), 434.

Moon, K. H., & Kim, Y. T. (2014). Medical treatment of ankylosing spondylitis. Hip & Pelvis, 26(3), 129–135.

NHS. (n.d.). Treatment.

Omar, M., Ben-Shabat, N., Tsur, A. M., Cohen, A. D., Watad, A., Amital, H., & Sharif, K. (2023). The association between ankylosing spondylitis and psychiatric disorders: Insights from a population based cross-sectional database. Journal of Affective Disorders, 323, 788–792.

Sarisoy, G., Durmuş, D., Böke, Ö., Cantürk, F., & Şahin, A. R. (2014). Coping with stress and body image in patients with ankylosing spondylitis. Noro Psikiyatri Arsivi, 51(2), 110–115.

Soleimanifar, N., Nicknam, M.H., Bidad, K., Jamshidi, A. R., Mahmoudi, M., Mostafaei, S., Hosseini-khah, Z., & Nikbin, B. (2019). Effect of food intake and ambient air pollution exposure on ankylosing spondylitis disease activity. Advances in Rheumatology, 59, 9.

Sun, L., Wu, R., Xue, Q., Wang, F., & Lu, P. (2016). Risk factors of uveitis in ankylosing spondylitis: An observational study. Medicine, 95(28), e4233.

Weissman, H. (2023, November 30). What causes spinal fusion in ankylosing spondylitis? GoodRx.

Wells, B. (n.d.). Tips for sleeping better with spondyloarthritis. Spondylitis Association of America.

Recommended For You

No items found.